tbuckley/cabot-search huggingface dataset:
Randomized Clinical Trial of Computerized and Clinician-Delivered CBT in Comparison With Standard Outpatient Treatment for Substance Use Disorders: Primary Within-Treatment and Follow-Up Outcomes
Authors: Brian D. Kiluk, Charla Nich, Matthew B. Buck, Kathleen A. Devore, Tami L. Frankforter, Donna M. LaPaglia, Srinivas B. Muvvala, Kathleen M. Carroll
Journal: American Journal of Psychiatry (2018)

Objective: Previous trials have demonstrated the efficacy and durability of computer-based cognitive-behavioral therapy (CBT4CBT) as an add-on to standard outpatient care in a range of treatment-seeking populations. In this study, the authors evaluated the efficacy and safety of CBT4CBT as a virtual stand-alone treatment, delivered with minimal clinical monitoring, and clinician-delivered cognitive-behavioral therapy (CBT) compared with treatment as usual in a heterogeneous sample of treatment-seeking outpatients with substance use disorders. Method: This was a randomized clinical trial in which 137 individuals who met DSM-IV-TR criteria for current substance abuse or dependence were randomly assigned to receive treatment as usual, weekly individual CBT, or CBT4CBT with brief weekly monitoring. Results: Rates of treatment exposure differed by group, with the best retention in the CBT4CBT group and the poorest in the individual CBT group. Participants who received CBT or CBT4CBT reduced their frequency of substance use significantly more than those who received treatment as usual. Six-month follow-up outcomes indicated continuing benefit of CBT4CBT (plus monitoring) over treatment as usual, but not for clinician-delivered CBT over treatment as usual. Analysis of secondary outcomes indicated that participants in the CBT4CBT group demonstrated the best learning of cognitive and behavioral concepts, as well as the highest satisfaction with treatment. Conclusions: This first trial of computerized CBT as a virtual stand-alone intervention delivered in a clinical setting to a diverse sample of patients with current substance use disorders indicated that it was safe, effective, and durable relative to standard treatment approaches and was well-liked by participants. Clinician-delivered individual CBT, while efficacious within the treatment period, was unexpectedly associated with a higher dropout rate and lower effects at follow-up.
Vaccination Coverage Among Children Aged 2 Years — U.S. Affiliated Pacific Islands, April–October, 2016
Authors: Ashley Tippins, Neil Murthy, Mehreen Meghani, Amy Solsman, Carter Apaisam, Merlyn Basilius, Maribeth Eckert, Peter Judicpa, Yolanda Masunu, Kelsey Pistotnik, Daisy Pedro, Jeremy Sasamoto, J. Michael Underwood
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

Vaccine-preventable diseases (VPDs) cause substantial morbidity and mortality in the United States Affiliated Pacific Islands (USAPI).* CDC collaborates with USAPI immunization programs to monitor vaccination coverage. In 2016, † USAPI immunization programs and CDC piloted a method for estimating up-to-date status among children aged 2 years using medical record abstraction to ascertain regional vaccination coverage. This was the first concurrent assessment of childhood vaccination coverage across five USAPI jurisdictions (American Samoa; Chuuk State, Federated States of Micronesia [FSM]; Commonwealth of the Northern Mariana Islands [CNMI]; Republic of the Marshall Islands [RMI]; and Republic of Palau).§ Differences in vaccination coverage between main and outer islands¶ were assessed for two jurisdictions where data were adequate.** Series coverage in this report includes the following doses of vaccines: ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP); ≥3 doses of inactivated poliovirus vaccine (IPV); ≥1 dose of measles, mumps, and rubella vaccine (MMR); ≥3 doses of Haemophilus influenzae type B (Hib) vaccine; ≥3 doses of hepatitis B (HepB) vaccine; and ≥4 doses of pneumococcal conjugate vaccine (PCV); i.e., 4:3:1:3:3:4. Coverage with ≥3 doses of rotavirus vaccine was also assessed. Completion of the recommended series of each of these vaccines†† was <90% in all jurisdictions except Palau. Coverage with the full recommended six-vaccine series (4:3:1:3:3:4) ranged from 19.5% (Chuuk) to 69.1% (Palau). In RMI and Chuuk, coverage was lower in the outer islands than in the main islands for most vaccines, with differences ranging from 0.9 to 66.8 percentage points. Medical record abstraction enabled rapid vaccination coverage assessment and timely dissemination of results to guide programmatic decision-making. Effectively monitoring vaccination coverage, coupled with implementation of data-driven interventions, is essential to maintain protection from VPD outbreaks in the region and the mainland United States.
Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance
Authors: Nobuaki Takahashi, Hsing-Yu Chen, Isaac S. Harris, Daniel G. Stover, Laura M. Selfors, Roderick T. Bronson, Thomas Deraedt, Karen Cichowski, Alana L. Welm, Yasuo Mori, Gordon B. Mills, Joan S. Brugge
Journal: Cancer Cell (2018)
Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit
Authors: Bertrand Guidet, Hans Flaatten, Ariane Boumendil, Alessandro Morandi, Finn H. Andersen, Antonio Artigas, Guido Bertolini, Maurizio Cecconi, Steffen Christensen, Loredana Faraldi, Jesper Fjølner, Christian Jung, Brian Marsh, Rui Moreno, Sandra Oeyen, Christina Agwald Öhman, Bernardo Bollen Pinto, Ivo W. Soliman, Wojciech Szczeklik, Andreas Valentin, Ximena Watson, Tilemachos Zafeiridis, Dylan W. De Lange
Journal: Intensive Care Medicine (2018)
Moral cues from ordinary behaviour
Authors: Suraiya Allidina, William A. Cunningham
Journal: Behavioral and Brain Sciences (2018)

Abstract People want to form impressions of others based on their moral behaviours, but the most diagnostic behaviours are rarely seen. Therefore, societies develop symbolic forms of moral behaviour such as conventional rituals and games, which are used to predict how others are likely to act in more serious moral situations. This framework helps explain why everyday behaviours are often moralized.
Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren’s syndrome
Authors: Efstathia K Kapsogeorgou, Aristea Papageorgiou, Athanase D Protogerou, Michael Voulgarelis, Athanasios G Tzioufas
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> Development of non-Hodgkin's lymphoma (NHL) is the major adverse outcome of Sjögren's syndrome (SS) affecting both morbidity and mortality. Preliminary evidence suggested that, although not deregulated compared with sicca controls, miR200b-5p levels are decreased in the minor salivary glands (MSGs) of SS patients with NHL. The aim of the current study was to evaluate the MSG expression of miR200b-5p in SS-associated NHLs and its potential predictive value for the identification of patients with SS susceptible to develop NHL. <h3>Methods</h3> miR200b-5p expression was investigated in MSG tissues of patients with SS who were at: (A) low risk and did not develop NHL during follow-up (n=27; median follow-up time on biopsy performance, range: 8.9 years, 1.33–14 years), (B) high-risk and diagnosed with NHL during follow-up (prelymphoma; n=17; median follow-up to until lymphoma diagnosis, range: 3.67 years, 0.42–8.5 years) and (C) had NHL (n=35), as well as non-SS sialadenitis controls (sarcoidosis and hepatitis C virus (HCV) infection, four each). The differential miR200b-5p expression, correlations with disease features and its discriminative/predictive value, was evaluated by appropriate statistical approaches. <h3>Results</h3> The MSG levels of miR200b-5p were significantly downregulated in patients with SS who will develop or have NHL and strongly discriminated (p&lt;0.0001) them from those without lymphoma or non-SS sialadenitis. Furthermore, they were reduced long before clinical onset of lymphoma, did not significantly change on transition to lymphoma and, importantly, were proved strong independent predictors of patients who will develop NHL (p&lt;0.0001). <h3>Conclusions</h3> These findings support that miR200b-5p levels in MSGs represent a novel predictive and possibly pathogenetic mechanism-related factor for the development of SS-associated NHL, since its expression is impaired years before lymphoma clinical onset.
Home spirometry in bronchiolitis obliterans after allogeneic haematopoietic cell transplant
Authors: Clémence Loiseau, François Lemonnier, Odile Randrianarivelo, Raphael Itzykson, Stéphanie Nguyen, Marie Hélène Becquemin, Colas Tcherakian, Madalina Uzunov, Emilie Catherinot, Elisabeth Rivaud, Hélène Salvator, Philippe Devillier, Laurent Sutton, Jean-Paul Vernant, Louis Jean Couderc, Nathalie Dhédin
Journal: European Respiratory Journal (2018)

Bronchiolitis obliterans syndrome (BOS) is a well-characterised late-onset noninfectious pulmonary complication of allogeneic haematopoietic stem cell transplantation (HSCT), occurring in 2% to 26% of recipients [1]. It is considered to be a pulmonary manifestation of graft versus host disease (GVHD) [2] and is associated with a mortality rate varying from 14% to 100% in historical series [3, 4]. Although immunosuppressive drugs are modestly effective, early diagnosis and treatment could improve its outcome [5]. After lung transplantation, home spirometry monitoring of pulmonary function allows early detection of BOS [6]; it is associated with a better response to steroids [7] and consequently is considered as a standard of care [8]. Our group was the first to report the use of home spirometry in 37 HSCT recipients [9]. More recently, Cheng et al . [10] showed a good correlation between home spirometry and classical laboratory spirometry in this population. We present here the incidence and long-term outcome of BOS occurring after HSCT in an extended cohort of 110 patients monitored with home spirometry. Long-term outcome of patients with BOS after HSCT with home spirometry is encouraging despite suboptimal adherence <http://ow.ly/mKfM30jDknz> We thank LVL Medical Company for technical assistance with home spirometry monitoring devices and Polly Gobin for English language revision.
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
Authors: Davendra P.S. Sohal, Erin B. Kennedy, Alok Khorana, Mehmet S. Copur, Christopher H. Crane, Ignacio Garrido-Laguna, Smitha Krishnamurthi, Cassadie Moravek, Eileen M. O’Reilly, Philip A. Philip, Ramesh K. Ramanathan, Joseph T. Ruggiero, Manish A. Shah, Susan Urba, Hope E. Uronis, Michelle W. Lau, Daniel Laheru
Journal: Journal of Clinical Oncology (2018)

Purpose In 2016, ASCO published a guideline to assist in clinical decision making in metastatic pancreatic cancer for initial assessment after diagnosis, first- and second-line treatment options, palliative and supportive care, and follow-up. The purpose of this update is to incorporate new evidence related to second-line therapy for patients who have experienced disease progression or intolerable toxicity during first-line therapy. Methods ASCO convened an Expert Panel to conduct a systematic review of the literature on second-line therapy published between June 2015 and January 2018. Recommendations on other topics covered in the 2016 Metastatic Pancreatic Cancer Guideline were endorsed by the Expert Panel. Results Two new studies were found that met the inclusion criteria. Recommendations For second-line therapy, gemcitabine plus nanoparticle albumin-bound paclitaxel should be offered to patients with first-line treatment with FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin), an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1, and a favorable comorbidity profile; fluorouracil plus nanoliposomal irinotecan can be offered to patients with first-line treatment with gemcitabine plus NAB-paclitaxel, an ECOG PS of 0 to 1, and a favorable comorbidity profile; fluorouracil plus irinotecan or fluorouracil plus oxaliplatin may be offered when there is a lack of availability of fluorouracil plus nanoliposomal irinotecan; gemcitabine or fluorouracil should be offered to patients with either an ECOG PS of 2 or a comorbidity profile that precludes other regimens. Testing select patients for mismatch repair deficiency or microsatellite instability is recommended, and pembrolizumab is recommended for patients with mismatch repair deficiency or high microsatellite instability tumors. Endorsed recommendations from the 2016 version of this guideline for computed tomography, baseline performance status and comorbidity profile, defining goals of care, first-line therapy, and palliative care are also contained within the full guideline text. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Exclusion from Resuscitation
Authors: R M Keatinge
Journal: Journal of the Royal Society of Medicine (1989)

Resuscitation was attempted for 156 (19.9%) of the 783 cases in St Thomas's Hospital, aged 16 or over, who suffered first cardiac or respiratory arrest of the current admission during the year to 13 April 1987. Seventeen (11%) of the 156 were discharged alive from hospital after resuscitation. All seventeen had been active outside the home before admission, and all except one remained so after discharge. The factors which were associated with exclusion from resuscitation attempts are analysed. Most accorded with known prognostic factors, but resuscitation was attempted for some persons who seemed to have little chance of benefiting from resuscitation attempts. Routine collection, analysis, and dissemination of information on pre-arrest characteristics in relation to their outcome, on which clinicians can base their decision to with-hold resuscitation in the event of an arrest, is recommended.
Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity
Authors: Emily S.J. Edwards, Julia Bier, Theresa S. Cole, Melanie Wong, Peter Hsu, Lucinda J. Berglund, Kaan Boztug, Anthony Lau, Emma Gostick, David A. Price, Michael O'Sullivan, Isabelle Meyts, Sharon Choo, Paul Gray, Steven M. Holland, Elissa K. Deenick, Gulbu Uzel, Stuart G. Tangye
Journal: Journal of Allergy and Clinical Immunology (2018)
IgG1<sup>+</sup> B‐cell immunity predates IgE responses in epicutaneous sensitization to foods
Authors: R. Jiménez‐Saiz, Y. Ellenbogen, J. F. E. Koenig, M. E. Gordon, T. D. Walker, D. Rosace, P. Spill, K. Bruton, J. Kong, K. Monteiro, J. Wen, E. I. Tuomanen, R. Kolbeck, D. K. Chu, S. Waserman, M. Jordana
Journal: Allergy (2018)

Abstract Background The generation of IgE‐mediated food allergy in humans is silent and only diagnosed upon manifestation of clinical symptoms. While experimental models have been used to investigate some mechanisms of allergic sensitization, the generation of humoral immunity and memory remains to be elucidated. Here, we defined the evolution of allergen‐specific B‐cell responses during epicutaneous sensitization to foods. Methods Wild‐type and genetic knockout animals, and drug or antibody strategies for cell depletion and immunoglobulin signaling blockade were used to investigate epicutaneous sensitization and disease progression; we analyzed allergen‐specific germinal centers and IgG1 + memory B cells by flow cytometry, evaluated humoral responses, and determined clinical reactivity (anaphylaxis). Results Epicutaneous sensitization caused microscopic skin damage, inflammation, and recruitment of activated dendritic cells to the draining lymph nodes. This process generated allergen‐specific IgG1 + germinal center B cells, serum IgG1, and anaphylaxis that was mediated by the alternative pathway. Whether we used peanut and/or ovalbumin from the egg white for sensitization, the allergen‐specific IgG1 + memory compartment predominantly exhibited an immature, pro‐germinal center phenotype (PDL‐2 − CD80 − CD35 + CD73 + ). Subsequent subclinical exposures to the allergen induced IgE + germinal center B cells, serum IgE, and likely activated the classical pathway of anaphylaxis. Conclusions Our data demonstrate that IgG1 + B‐cell immunity against food allergens in epicutaneous sensitization precedes the generation of IgE responses. Therefore, the assessment of allergen‐specific cellular and humoral IgG1 + immunity may help to identify individuals at risk of developing IgE‐mediated food allergy and hence provide a window for therapeutic interventions.
Response by Puymirat et al to Letter Regarding Article, “Acute Myocardial Infarction Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015”
Authors: Etienne Puymirat, Tabassome Simon, Nicolas Danchin
Journal: Circulation (2018)
Additive manufacturing of prototype elements with process interfaces for continuously operating manufacturing lines
Authors: Cosima Hirschberg, Mikkel Schmidt Larsen, Johan Peter Bøtker, Jukka Rantanen
Journal: Asian Journal of Pharmaceutical Sciences (2018)

Rapid prototyping based on in silico design and 3D printing enables fast customization of complex geometries to multiple needs. This study utilizes, additive manufacturing for rapid prototyping of elements for continuously operating mixing geometries including interfaces with process analytical technology (PAT) tools, to show that 3D printing can be used for prototyping of both parts of production line and PAT interfacing solution. An additional setup was designed for measuring the dynamic calibration samples for a semi-quantitative near infrared (NIR) spectroscopic model. The powder was filled in a small calibration chamber and in-line NIR spectra of calibration samples were collected from moving material while mimicking the powder flow dynamics in a typical continuous mixer. This dynamic powder mixing system was compared with a static powder calibration model where the NIR probe was placed at different positions on a static sample. Principal component analysis (PCA) revealed that the 3D printed device with dynamic measurement of the NIR spectra had more potential for quantitative analysis. With the prototype continuous mixer, two differently placed process interfaces for NIR spectroscopic monitoring of the powder mixing were evaluated. With this approach, the importance of positioning the process analytical tools to assess the blend uniformity could be demonstrated. It was also observed that with the longer mixing geometry, a better mixing result was achieved due to a larger hold up volume and increased residence time.
Abstract 13077: Maternal and Fetal Outcomes Among Pregnant Women With Frequent Premature Ventricular Complexes
Authors: Calvin Ka Wing Tong, Marc W Deyell, Miriam Wheeler, Marla Kiess, Valerie Rychel, Jasmine Grewal
Journal: Circulation (2015)

Introduction: Premature ventricular complexes (PVCs) in pregnancy are being increasingly recognized and many women have associated symptoms. Although thought to be benign, there is limited data on maternal and fetal outcomes in pregnancies with frequent PVCs. The objectives of this study were to describe the PVC burden and patterns, and to assess maternal and fetal outcomes in pregnancies with frequent PVCs. Methods: In this prospective observational cohort study, 40 consecutive pregnancies referred to our institution between January 2010 and March 2015 with PVC burden of greater than 0.1% on Holter studies were included. We reviewed electrocardiograms to identify PVC morphologies and Holter studies to determine PVC burden. PVC burden were stratified into low (n = 20) and high (n = 20) severity based on the median PVC burden of 6.8%. Student’s t-tests and Fisher’s exact test were used to evaluate difference in maternal and fetal outcomes by severity of PVC burden and beta-blocker (BB) use. Paired t-test was used to compare changes in PVC burden from antepartum to postpartum. Pearson analysis was performed to evaluate correlation between PVC burden and cardiac function. Results: Antepartum palpitations, pre-syncope, congestive heart failure, syncope, and deterioration in NYHA class were present in 70%, 25%, 5%, 2.5%, and 10% respectively. Fifty-five percent continued to have palpitation postpartum. Ninety-two percent of PVCs originated from right ventricular outflow tract. PVC burden decreased from 9.3 ± 9 % antepartum to 3.9 ± 5.4 % postpartum ( p = 0.118). There was no correlation between PVC burden and left ventricular end diastolic and end systolic dimensions, and left ventricular ejection fraction (r = 0.08, p = 0.74; r = 0.03, p = 0.92; r = -0.16, p = 0.50). Gestation at delivery was 39 ± 2 weeks with newborn weight of 3251 ± 576 grams. APGAR scores at 1 and 5 minutes were 8 ± 2 and 9 ± 1 respectively. One newborn had intrauterine growth restriction and 3 had meconium liquor. There was no difference in the above outcomes in subgroup analyses based on severity of PVC burden and BB use. Conclusions: Maternal and fetal outcomes in pregnancies with frequent PVCs were favorable. Severity of PVC burden and BB use did not have significant impact on maternal and fetal outcomes.
Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations
Authors: Stefan O. Ciurea, Abhishek Chilkulwar, Rima M. Saliba, Julianne Chen, Gabriela Rondon, Keyur P. Patel, Haitham Khogeer, Abdul R. Shah, Brion V. Randolph, Jorge M. Ramos Perez, Uday Popat, Chitra M. Hosing, Qaiser Bashir, Rohtesh Mehta, Gheath Al-Atrash, Jin Im, Issa F. Khouri, Partow Kebriaei, Richard E. Champlin
Journal: Blood (2018)
CARD9S12N facilitates the production of IL-5 by alveolar macrophages for the induction of type 2 immune responses
Authors: Xia Xu, Jin-Fu Xu, Guoxing Zheng, Hai-Wen Lu, Jie-Lin Duan, Wei Rui, Jian-Hong Guan, Li-Qing Cheng, Dan-Dan Yang, Ming-Chao Wang, Quan-Zhen Lv, Jian-Xiong Li, Xueqiang Zhao, Chun-Xia Chen, Peng Shi, Xin-Ming Jia, Xin Lin
Journal: Nature Immunology (2018)